MEDGENERA
  • Sections
    • NEWLY PUBLISHED
    • News from Asia-pacific
    • News from Europe
    • News from USA
    • MEDGENERA ORIGINAL
    • ASSESSMENT
    • MARKET INSIGHTS
    • DRUG TRIAL
    • PROGRESSIVE REVIEW
    • APPS & IMPLANTS
  • About us
  • Plans
  • Education
  • Get Online Training
  • Login
  • Webinar
0
  • Login
  • Get 1-Free month
  • Online Course
  • About us
  • BIORISE
  • Plans
  • BUSINESS
  • CAREER
  • HEALTHCARE & MEDICINE
  • IN-DEPTH STORIES
  • KNOWLEDGE CENTRE
  • MEDGENERA EXCLUSIVE
  • NEWLY PUBLISHED
  • News from Asia-pacific
  • News from Europe
  • News from USA
  • RESOURCE CENTRES
  • TECHNOLOGY

Category: News from Asia-pacific

Proportion
Pankaj MishraJuly 28, 2018

7 New Ideas to Start a Healthcare Business in India (2018)

Seven new #healthcare #business ideas in India in 2018. Which one would you prefer to pursue?

Proportion
Tiash SahaJune 5, 2018

Mylan-Biocon Bags FDA Nod for Biosimilar Drug ‘Fulphila’, Reduces Infection Risk in Cancer Patients

US FDA approved Fulphila (pegfilgrastim-jmdb) – a biosimilar to Neulasta for reducing the chances of infection in patients with non-myeloid (non-bone marrow) cancer during chemotherapy. It is the first pegfilgrastim biosimilar that is approved by the US FDA.

Proportion
Tiash SahaMay 29, 2018

It’s not only about Nipah Virus in Kerala!!!

This disease is not new in India but has revisited for the third time after previously outbreaking in the two districts of West Bengal – Siliguri and Nadia in 2001 and 2007 respectively. High fatality rate (about 70 percent) and easy person-to-person transmission of the disease had already been established during its previous encounters but still, there is no vaccine for the prevention or cure of the disease and only supportive treatment is given for the disease-related complications including neurological and respiratory complications.

Proportion
Tiash SahaMay 10, 2018

IIT Roorkee’s Innovative Bone Implant Technology Could Tap Emerging Orthopedic Market

Indian Institute of Technology Roorkee (IIT Roorkee) scientists have developed an improved orthopedic implant technology for sustained drug release. Currently, the technology is with the company, Biotech Consortium India Limited (BCIL) for transfer, for the commercialization of the technology.

Proportion
Tiash SahaApril 26, 2018

First Drug to Treat Polycystic Kidney Disease Bags FDA Approval

First drug treatment- Jynarque (tolvaptan) to slow down the decline in kidney function in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD) received USFDA approval. The drug is developed by Japanese biopharma, Otsuka Pharma.

Proportion
Vikash KumarApril 12, 2018

Delhi-Based Healthcare Fintech Startup Raises $1 M in Seed Funding Round

Delhi-based healthcare financing startup, LetsMD has raised $1 million a pre-series A funding round led by SRI Capital.

Proportion
Tiash SahaMarch 31, 2018

New Potential Immuno-Oncology Drug for Blood Cancer Received Orphan Drug Status

Chinese biotech, Maxinovel Pharma’s immuno-oncology drug candidate- MAX-40279 received Orphan Drug designation from the US FDA for the treatment of ...

Proportion
Tiash SahaMarch 23, 2018

First Japanese Company Shionogi Receives CARB-X Funding for New Antibiotics Development against Superbugs

KEY POINTS CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) founded by US government Agencies and Wellcome Trust, London funds companies to ...

Proportion
Tiash SahaMarch 14, 2018

AI-Based Software EyeArt™ in Smartphone Could Prevent Vision Loss in 90% Diabetic People

KEY POINTS One in five diabetic Indians is at risk of developing diabetic retinopathy, which can lead to blindness. Eyenuk’s ...

Proportion
Tiash SahaMarch 9, 2018

A Chinese Biotech Raises $90 M in Series A for CAR-T Cell Therapy Development

Shanghai-based biotech JW Therapeutics has raised $90 million in Series A funding round, led by Temasek, Sequoia Capital China, and ...

  • 1
  • 2
  • 3
Privacy Policy Terms Payment Policy Education Contact Us About us